What is the Fiscal Year for Cue Biopharma?
Date: November 13, 2026
Cue Biopharma's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Boston, Massachusetts
Industry
Biotechnology Research
Stock Symbol
CUE
Website
https://cuebiopharma.comDescription
Cue Biopharma is a clinical-stage biopharmaceutical company focused on advancing a robust portfolio of therapies aimed at enabling functional cures across allergic and autoimmune diseases. Our lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action, currently in Phase 2 development for allergic diseases. In addition, we developed the Immuno-STAT® platform designed to engineer therapies that selectively target disease-specific T cells in vivo without broad immune modulation. CUE-401, our lead asset targeting autoimmune disease was developed using the Immuno-STAT® platform. It is a bifunctional IL-2 and TGF-β molecule advancing towards Phase 1 and was designed to restore immune balance utilizing Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Cue Biopharma and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.